Literature DB >> 24926671

HSV-1 and HSV-2 seroprevalence in the united states among asymptomatic women unaware of any herpes simplex virus infection (Herpevac Trial for Women).

Joann M Schulte1, Abbie R Bellamy1, Edward W Hook1, David I Bernstein1, Myron J Levin1, Peter A Leone1, Marcia L Sokol-Anderson1, Marian G Ewell1, Peter A Wolff1, Thomas C Heineman1, Robert B Belshe1.   

Abstract

OBJECTIVES: Recent evidence suggests that the epidemiology of herpes simplex viruses (HSVs) is changing because fewer HSV-1 infections are acquired in childhood and increased sexual transmission of HSV-1 is reported. The objective of the study was to assess the seroprevalence of type-specific antibodies to HSV-1 and HSV-2 in the United States.
METHODS: We used the Western blot antibody screening data from a large phase III vaccine efficacy trial (Herpevac Trial for Women) to assess the seroprevalence of type-specific antibodies to HSV-1 and HSV-2 in the United States.
RESULTS: The antibody status of 29,022 women (>31,000 women interviewed and then had their blood drawn for the HSV testing [29,022 women]) between the ages of 18 and 30 years in the United States revealed that increasing age was associated with increasing seroprevalence to HSV. Overall, in asymptomatic women unaware of any HSV infection, HSV-1/-2 status was positive/negative in 45%, negative/positive in 5%, positive/positive in 7%, negative/negative in 38%, and indeterminate in 5%. HSV-1 infections were more common in Hispanic and non-Hispanic black women and in the US northeast and in individuals living in urban areas. HSV-2 was more common in non-Hispanic black women, the US south, and in urban areas.
CONCLUSIONS: Seronegative status for both HSV-1 and HSV-2 was the second most common finding after positive antibody to HSV-1 but negative antibody to HSV-2. Despite recent changes in genital herpes epidemiology, most women acquired HSV-1 but not HSV-2 infections before 18 years of age. Among participants screened for study participation and who were unaware of any HSV infection, progressively higher prevalence of the HSV-1 or HSV-2 antibody was observed in older subjects. Many women who test positive for HSV-1 and/or HSV-2 are unaware of their status.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24926671     DOI: 10.1097/SMJ.0000000000000062

Source DB:  PubMed          Journal:  South Med J        ISSN: 0038-4348            Impact factor:   0.954


  10 in total

Review 1.  Novel composite efficacy measure to demonstrate the rationale and efficacy of combination antiviral-anti-inflammatory treatment for recurrent herpes simplex labialis.

Authors:  Christopher M Hull; Myron J Levin; Stephen K Tyring; Spotswood L Spruance
Journal:  Antimicrob Agents Chemother       Date:  2013-12-16       Impact factor: 5.191

Review 2.  Human Immunodeficiency Virus, Other Sexually Transmitted Infections, and Sexual and Reproductive Health in Lesbian, Gay, Bisexual, Transgender Youth.

Authors:  Sarah M Wood; Caroline Salas-Humara; Nadia L Dowshen
Journal:  Pediatr Clin North Am       Date:  2016-12       Impact factor: 3.278

3.  The Current State of Vaccine Development for Ocular HSV-1 Infection.

Authors:  D J Royer; A Cohen; Djj Carr
Journal:  Expert Rev Ophthalmol       Date:  2015-04-01

Review 4.  Fraternal Twins: The Enigmatic Role of the Immune System in Alphaherpesvirus Pathogenesis and Latency and Its Impacts on Vaccine Efficacy.

Authors:  Barry T Rouse; D Scott Schmid
Journal:  Viruses       Date:  2022-04-21       Impact factor: 5.818

5.  Multicenter Evaluation of Meridian Bioscience HSV 1&2 Molecular Assay for Detection of Herpes Simplex Virus 1 and 2 from Clinical Cutaneous and Mucocutaneous Specimens.

Authors:  Matthew L Faron; Nathan A Ledeboer; Anami Patel; Safedin H Beqa; Belinda Yen-Lieberman; Debra Kohn; Amy L Leber; Donna Mayne; William I Northern; Blake W Buchan
Journal:  J Clin Microbiol       Date:  2016-05-18       Impact factor: 5.948

6.  Characterization of the C-Terminal Nuclease Domain of Herpes Simplex Virus pUL15 as a Target of Nucleotidyltransferase Inhibitors.

Authors:  Takashi Masaoka; Haiyan Zhao; Danielle R Hirsch; Michael P D'Erasmo; Christine Meck; Brittany Varnado; Ankit Gupta; Marvin J Meyers; Joel Baines; John A Beutler; Ryan P Murelli; Liang Tang; Stuart F J Le Grice
Journal:  Biochemistry       Date:  2016-02-01       Impact factor: 3.162

Review 7.  Extracellular Vesicles in Viral Infections of the Nervous System.

Authors:  Naseer A Kutchy; Eric S Peeples; Susmita Sil; Ke Liao; Ernest T Chivero; Guoku Hu; Shilpa Buch
Journal:  Viruses       Date:  2020-06-28       Impact factor: 5.048

8.  Herpes simplex virus: global infection prevalence and incidence estimates, 2016.

Authors:  Charlotte James; Manale Harfouche; Nicky J Welton; Katherine Me Turner; Laith J Abu-Raddad; Sami L Gottlieb; Katharine J Looker
Journal:  Bull World Health Organ       Date:  2020-03-25       Impact factor: 9.408

9.  ThymicPeptides Reverse Immune Exhaustion in Patients with Reactivated Human Alphaherpesvirus1 Infections.

Authors:  Anna Hymos; Ewelina Grywalska; Janusz Klatka; Maria Klatka; Izabela Korona-Głowniak; Jacek Roliński
Journal:  Int J Mol Sci       Date:  2020-03-30       Impact factor: 5.923

10.  TORCH Antibodies Among Pregnant Women and Their Newborns Receiving Care at Kilimanjaro Christian Medical Centre, Moshi, Tanzania.

Authors:  Aliasgher M Saajan; Mramba Nyindo; Joshua G Gidabayda; Mohammed S Abdallah; Shaneabbas H Jaffer; Aliasgher G Mukhtar; Tima M Khatibu; Rune Philemon; Grace D Kinabo; Blandina T Mmbaga
Journal:  East Afr Health Res J       Date:  2017-07-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.